Precision Medicine and Companion Diagnostics In a recent Medical Device Network interview, Russell Bradley, President and General Manager of CNSide Diagnostics, emphasized the essential role of companion diagnostics (CDx) in advancing targeted cancer therapies. As...

Collaboration Spotlight: Advancing Leptomeningeal Metastases Research Last week, the leadership teams from Plus Therapeutics and CNSide Diagnostics came together onsite at #SNOASCO2025 in Baltimore, Maryland. Their jointly sponsored symposium on leptomeningeal...

Expert Insights on CNS Metastases Russell Bradley, President and General Manager of CNSide Diagnostics, recently sat down with Pharmafile to discuss one of oncology’s greatest challenges: central nervous system (CNS) cancer metastases. CNS metastases, including...

Mark Your Calendars: A Must-Attend Symposium on LM We’re excited to announce that CNSide Diagnostics will participate in the upcoming 2025 SNO/ASCO CNS Metastases Conference, held in Baltimore, Maryland. Date & Time: Thursday, August 14, 2025, at 6:15 PMLocation:...

Our Mission: Transforming Cancer Diagnostics At CNSide Diagnostics, our mission is clear: to improve patient outcomes by delivering cutting-edge diagnostics that empower oncologists with personalized, effective treatment strategies. Cancer that spreads to the central...

Precision Diagnostics for CNS Metastases Emerging data highlights the potential of the CNSide® cerebrospinal fluid (CSF) assay platform as a sensitive and precise tool for diagnosing and longitudinally monitoring leptomeningeal disease (LMD), a life-threatening...

Launch Update: CNSide® Diagnostic Now Commercially Available in Texas On July 31, 2025, Plus Therapeutics announced that its wholly-owned subsidiary, CNSide Diagnostics, LLC, is launching the CNSide® cerebrospinal fluid (CSF) assay platform in Texas starting August...

CNSide at the Forefront of CNS Metastases Innovation in 2025 On July 10, 2025, Plus Therapeutics announced that its subsidiary, CNSide Diagnostics, LLC, will feature two compelling presentations at the 2025 SNO/ASCO CNS Metastases Conference, taking place August...

On June 26, 2025, Plus Therapeutics delivered a comprehensive business update for its subsidiary, CNSide Diagnostics, unveiling its strategy to enter the U.S. market with the CNSide CSF assay platform (Source: ir.plustherapeutics.com). This update marks an important...

Plus Therapeutics positions CNSide for rapid growth by appointing seasoned leadership In a strategic move to strengthen its diagnostics division, Plus Therapeutics recently named Russell Bradley as President & General Manager of CNSide, alongside Dr. Marc Hedrick...